Recombinant Protein Market Sales Likely to Surge at Exceptional Rate during Forecast Period, 2017 - 2022
Recombinant proteins play an imperative role in treating various diseases, such as hemophilia. Majority of the recombinant proteins used are human proteins, in order to compensate the functional proteins in vivo defects by increasing the protein function in a body. This Fact.MR report analyzes
the expansion of global recombinant protein market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.
A new report published by Fact.MR estimates the global recombinant protein market to witness expansion at a moderate CAGR during the forecast period 2017 to 2022. Revenues from the global recombinant protein market will reach nearly US$ 460 Mn by 2022-end. In the past century, the recombinant DNA technology was mere imagination that desirable characteristics can be ameliorated in the living bodies through controlling expressions of target genes. By virtue of the recombinant DNA technology, vital proteins needed for dietary purposes and health problems are being produced affordably, safely and sufficiently.
As such, recombinant protein is playing a pivotal role in boosting the health conditions through development of new vaccines and pharmaceuticals. Erythropoietin by genetically modified bacteria and production of new types of experimental mutant mice and synthesis of synthetic human insulin for research purposes are prime examples of genetic engineering in health.
The emergence of recombinant DNA technology has revolutionized the development in biology and paved way for a series of dramatic changes. Given most biotechnology pharmaceuticals are recombinant in nature, the recombinant protein plays a huge role against lethal diseases. Accordingly, the U.S. FDA has approved more recombinant drugs in the past decade.
Recombinant DNA technology is a rapidly developing field and researchers have been coming up with novel devices, approaches and engineered products for use in various sectors such as health, agriculture and environment. For instance, Epoetin alfa is a new and popular recombinant protein which can be aptly used in curing anemia. Similarly, Lispro as compared with regular human insulin, is a fast acting and well effective recombinant insulin.
Recombinant Protein Market: Overview
The report offers an exhaustive assessment on the recombinant protein market with quantitative and qualitative analysis. Further, the report offers a clear picture with respect to dynamics of recombinant protein market, including drivers, trends, opportunities, and restraints. These aspects are indispensable and possess potency to impact the growth of the recombinant protein market. Besides, the report delves into the segregation of the recombinant protein market to provide a robust picture of recombinant protein market.
Access Detailed Report Summary: https://www.factmr.com/report/186/recombinant-protein-market
North America to Remain Dominant in the Market
North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.
Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.
Validation of the information in the report is done through primary sources, including in-person interactions, surveys, view of seasoned analyst, interviews and in-person interactions and insights of analyst coupled with secondary sources incorporating trade journals, verified paid sources, resourceful databases and trade journals. Absolute dollar opportunity analysis has also formed basis for the robust analysis of the report.
Recombinant Protein Market: Competitive Landscape
The report also includes competitive scenario of the recombinant protein market, including competition intensity mapping with respect to market taxonomy; competition dashboard and company profiles. The section, based on Porters’ Five Force Analysis, also sheds light on financials overview, strategies, product portfolio and recent developments.
Leading players in the global recombinant protein market include Abcam plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., BPS Bioscience Inc., PerkinElmer, Inc., Crown Bioscience, Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich, and Thermo Fisher Scientific, Inc.
the expansion of global recombinant protein market till date, and provides key insights on the growth of the market during the forecast period, 2017-2022.
A new report published by Fact.MR estimates the global recombinant protein market to witness expansion at a moderate CAGR during the forecast period 2017 to 2022. Revenues from the global recombinant protein market will reach nearly US$ 460 Mn by 2022-end. In the past century, the recombinant DNA technology was mere imagination that desirable characteristics can be ameliorated in the living bodies through controlling expressions of target genes. By virtue of the recombinant DNA technology, vital proteins needed for dietary purposes and health problems are being produced affordably, safely and sufficiently.
As such, recombinant protein is playing a pivotal role in boosting the health conditions through development of new vaccines and pharmaceuticals. Erythropoietin by genetically modified bacteria and production of new types of experimental mutant mice and synthesis of synthetic human insulin for research purposes are prime examples of genetic engineering in health.
The emergence of recombinant DNA technology has revolutionized the development in biology and paved way for a series of dramatic changes. Given most biotechnology pharmaceuticals are recombinant in nature, the recombinant protein plays a huge role against lethal diseases. Accordingly, the U.S. FDA has approved more recombinant drugs in the past decade.
Recombinant DNA technology is a rapidly developing field and researchers have been coming up with novel devices, approaches and engineered products for use in various sectors such as health, agriculture and environment. For instance, Epoetin alfa is a new and popular recombinant protein which can be aptly used in curing anemia. Similarly, Lispro as compared with regular human insulin, is a fast acting and well effective recombinant insulin.
Recombinant Protein Market: Overview
The report offers an exhaustive assessment on the recombinant protein market with quantitative and qualitative analysis. Further, the report offers a clear picture with respect to dynamics of recombinant protein market, including drivers, trends, opportunities, and restraints. These aspects are indispensable and possess potency to impact the growth of the recombinant protein market. Besides, the report delves into the segregation of the recombinant protein market to provide a robust picture of recombinant protein market.
Access Detailed Report Summary: https://www.factmr.com/report/186/recombinant-protein-market
North America to Remain Dominant in the Market
North America will continue to retain its dominance in the global recombinant protein market, with sales projected to reach nearly US$ 150 Mn by 2022-end. Europe is estimated to be the second most lucrative market for recombinant protein throughout the forecast period. The market in Middle East & Africa (MEA) is anticipated to witness a sluggish expansion through 2022.
Recombinant proteins factoring molecular growth will remain the most lucrative product in the market, followed by checkpoint regulators. In addition, sales of growth factors, and cytokines are poised to exhibit similar CAGRs through 2022. However, sales of chemokines are estimated to register the fastest expansion through 2022. Demand for enzymes & inhibitors will continue to be sluggish throughout the forecast period.
Validation of the information in the report is done through primary sources, including in-person interactions, surveys, view of seasoned analyst, interviews and in-person interactions and insights of analyst coupled with secondary sources incorporating trade journals, verified paid sources, resourceful databases and trade journals. Absolute dollar opportunity analysis has also formed basis for the robust analysis of the report.
Recombinant Protein Market: Competitive Landscape
The report also includes competitive scenario of the recombinant protein market, including competition intensity mapping with respect to market taxonomy; competition dashboard and company profiles. The section, based on Porters’ Five Force Analysis, also sheds light on financials overview, strategies, product portfolio and recent developments.
Leading players in the global recombinant protein market include Abcam plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., BPS Bioscience Inc., PerkinElmer, Inc., Crown Bioscience, Inc., GenScript Corporation, Merck Millipore Limited, Sigma Aldrich, and Thermo Fisher Scientific, Inc.
Comments
Post a Comment